Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2007
11/27/2007US7300936 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors
11/27/2007US7300935 Gonadotropin-releasing hormone antagonistic activity, therapy of prostatic cancer, endometriosis, precocious puberty; N-(4-(1-(2,6-difluorobenzyl)-5-(((2-ethoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea
11/27/2007US7300933 Diazabicyclic biaryl derivatives
11/27/2007US7300928 Benzimidazolidinone derivatives as muscarinic agents
11/27/2007US7300927 Method for treating or preventing Alzheimer's disease
11/27/2007US7300925 treating psoriasis with e.g. 19-nor-2beta-ethyl-1alpha,25-dihydroxyvitamin D3
11/27/2007US7300922 Enhancing or inhibiting the biological activity of nucleic acid ligands by administrating a modulator, to change the binding of the nucleic acid ligand for its target or degrading or cleaving
11/27/2007US7300677 Methods of reducing β-amyloid polypeptides
11/27/2007CA2525874C Pharmaceutical compositions of varenicline
11/27/2007CA2391333C Sustained release formulation of a peptide and a copolymer
11/27/2007CA2379695C Compounds for modulating the rage receptor
11/27/2007CA2335328C A substituted triazolo-pyridazine derivative, pharmaceutical compositions made therefrom
11/27/2007CA2309380C Viscous compositions containing carbon dioxide
11/27/2007CA2271683C Coated particles, methods of making and using
11/27/2007CA2264097C Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
11/23/2007CA2589819A1 Method for treatment of neurodegenerative disorders
11/22/2007WO2007134245A2 Elastin-like polymer delivery vehicles
11/22/2007WO2007134034A1 Polymorph forms of (2s) - (4e) -n-methyl-5- (3-isopropoxypyridin) yl] -4-penten-2-amine for the treatment of central nervous system disorders
11/22/2007WO2007133812A2 Improved carriers for delivery of nucleic acid agents to cells and tissues
11/22/2007WO2007133749A2 Methods and compositions for treating and preventing peripheral nerve damage
11/22/2007WO2007133155A1 Nicotinic acetylcholine receptor ligands 101
11/22/2007WO2007133141A1 Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
11/22/2007WO2007133140A1 Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
11/22/2007WO2007132948A1 Cinnamoyl compound and use thereof
11/22/2007WO2007132945A1 Cinnamoyl compound and use thereof
11/22/2007WO2007132893A1 Suppressor of expression of mcp-1, and ameliorating agent for inflammatory disease, pharmaceutical, supplement, food, beverage or food additive using the suppressor
11/22/2007WO2007132825A1 Pharmaceutical agent
11/22/2007WO2007132784A1 Antipsychotic drug and remedy for cognitive abnormality containing anthraquinone derivative as the active ingredient
11/22/2007WO2007132718A1 Solid preparation comprising adenosine 5'-triphosphate or physiologically acceptable salt thereof
11/22/2007WO2007132307A1 Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
11/22/2007WO2007131846A1 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
11/22/2007WO2007131357A1 Pharmaceutical composition having reduced abuse potential
11/22/2007WO2007131329A1 Treatment of ubiquitin-proteasome system dysfunction related disorders
11/22/2007WO2007110627A3 3,7-diamino-10h-phenothiazine salts and their use
11/22/2007WO2007108002A3 Use of digitalis-like compounds in the treatment of affective disorders
11/22/2007WO2007103432A3 Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders
11/22/2007WO2007095611A3 Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine
11/22/2007WO2007093183A3 Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
11/22/2007WO2007081909A3 Forms of dolasetron mesylate and processes for their preparation
11/22/2007WO2007027225A3 Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
11/22/2007WO2007024599A3 Comination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof
11/22/2007US20070270581 Storage stability; mixture of tetrahydrobiopterin and excipient
11/22/2007US20070270500 Compositions Comprising Cyclohexylamines and Aminoadamantanes
11/22/2007US20070270497 Agent For Recovery From Cerebral Fatigue
11/22/2007US20070270493 Composition with Preventive or Improvement Effect on Stress-Induced Brain Function Impairment and Related Symptoms or Diseases
11/22/2007US20070270491 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
11/22/2007US20070270490 Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
11/22/2007US20070270474 Pyrazole compounds for treatment of neurodegenerative disorders
11/22/2007US20070270471 Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine
11/22/2007US20070270469 e.g. 4-(5-{(1R)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine hydrochloride; glutamate mGluR5 receptor modulator; antidepressant, anxiolytic, analgesic agent; neurodegenerative disorder
11/22/2007US20070270468 e.g. 4-(5-{(1R)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine hydrochloride; glutamate mGluR5 receptor modulator; antidepressant, anxiolytic, analgesic agent; neurodegenerative disorder
11/22/2007US20070270467 Substituted piperidines as modulators of dopamine neurotransmission
11/22/2007US20070270466 Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists
11/22/2007US20070270463 such as N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-quinol-6-ylmethylsulfonamide; azeotropic distillation, crystallization; central nervous system disorders
11/22/2007US20070270458 Nicotinic Acetylcholine Receptor Ligands
11/22/2007US20070270452 Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
11/22/2007US20070270435 Novel Compounds
11/22/2007US20070270432 Novel Method
11/22/2007US20070270430 Methods of Treating Cognitive Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives
11/22/2007US20070270428 Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders
11/22/2007US20070270426 Compounds for the treatment of neurodegenerative disorders
11/22/2007US20070270421 Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide
11/22/2007US20070270420 Heteroaryl compounds useful as inhibitors of gsk-3
11/22/2007US20070270418 Inhibitors of P38 and Methods of Using the Same
11/22/2007US20070270415 Benzothiadiazine compounds
11/22/2007US20070270411 Novel Diazepine Compounds as Ligands of the Melanocortin 1 and/or 4 Receptors
11/22/2007US20070270403 Clozapine and Cocaine Effects on Dopamine and Serotonin Release in Nucleus Accumbens During Psychostimulant Behavior and Withdrawal
11/22/2007US20070270402 (+) or (-)-9-(piperazin-1-yl)-9,10-dihydropyrrolo[2,1-b][1,3]benzothiazepine; schizophrenia, paranoid states, manic-depressive states, social regression, personality regression, hallucination, appetite disorders
11/22/2007US20070270375 Obtained from plants of Barringtonia species which are derived from Barringtoside A and Barringtoside C as precursor compounds which especially have an arabinopyranosyl substituent at 21 position, which may optionally be further substituted with benzoyl, dibenzoyl, methyl butanoyl, at 3 or 4 position
11/22/2007US20070270353 Intrathecal administration of ziconotide, an Omega-conopeptide, and the anitoxidant methionine, and an analgesic selected from morphine, hydromorphone, fentanyl, sufentanil, and buprenorphine; ziconotide retains its potency and is physically and chemically compatible with the analgesic
11/22/2007US20070270352 Method of Treatment
11/22/2007US20070270342 Biotinylated hexadecasaccharides, preparation and use thereof
11/22/2007US20070270337 Pharmaceutical Compositions for Preventing or Treating Th1-Mediated Immune Diseases
11/22/2007US20070270332 Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
11/22/2007US20070269538 Method for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs
11/22/2007US20070269528 A Omega-conopeptide, and the anitoxidant methionine, and either clonidine or baclofen; ziconotide retains its potency and is physically and chemically compatible with the analgesic; for intrathecal administration
11/22/2007US20070269516 Controlled release matrix
11/22/2007US20070269511 Solid pharmaceutical compositions containing pregabalin
11/22/2007US20070269510 Solid Unit Dosage Forms of 5-Ht1 Agonist
11/22/2007US20070269505 Tamper Resistant Co-Extruded Dosage Form Containing An Active Agent And An Adverse Agent And Process Of Making Same
11/22/2007US20070269429 Treatment with anti-erbb2 antibodies
11/22/2007US20070269427 Therapeutical Use of Anti-Myelin Associated Glycoprotein (Mag) Antibodies
11/22/2007US20070269417 Nicotine delivery systems
11/22/2007US20070269393 Topical anesthetic formulation
11/22/2007US20070269374 4-[(4-N,N-diethylaminocarbonyl)phenyl]-spiro[2H,1-benzopyran-2,4'-piperidine; ligands of delta opioid receptor; analgesic, anxiolitic, antidepressant, analgesic; gastrointestinal disorders, neurodegenerative diseases; side effect reduction
11/22/2007CA2652610A1 Nicotinic acetylcholine receptor ligands 101
11/22/2007CA2652500A1 Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
11/22/2007CA2652499A1 Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
11/22/2007CA2652015A1 Methods and compositions for treating and preventing peripheral nerve damage
11/22/2007CA2651933A1 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
11/22/2007CA2651813A1 Neurogenesis by modulating angiotensin
11/22/2007CA2651629A1 Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
11/22/2007CA2649961A1 Polymorph forms of (2s) - (4e) -n-methyl-5- (3-isopropoxypyridin) yl] -4-penten-2-amine for the treatment of central nervous system disorders
11/22/2007CA2628031A1 Once-daily administration of central nervous system drugs
11/21/2007EP1857551A2 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
11/21/2007EP1857463A1 Peptide having neuroprotective effects
11/21/2007EP1857459A2 Pyrazolopyrimidine compound and a process for preparing the same
11/21/2007EP1857121A2 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
11/21/2007EP1857115A2 Using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
11/21/2007EP1857110A2 Hormone replacement therapy
1 ... 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 ... 1833